2-氯-6-(三氟甲基)噻唑并[4,5-b]吡啶 | 884860-62-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-氯-6-(三氟甲基)噻唑并[4,5-b]吡啶
• 中文别名: 2-氯-6-(三氟甲基)噻唑并[4,5-B]吡啶
• 英文名称: 7a,2-chloro-6-(trifluoromethyl)thiazolo[4,5-b]pyridine
• 英文别名: 2-chloro-6-(trifluoromethyl)thiazolo[4,5-b]pyridine；2-chloro-6-(trifluoromethyl)-[1,3]thiazolo[4,5-b]pyridine
• CAS: 884860-62-2
• 化学式: C₇H₂ClF₃N₂S
• 分子量: 238.62
• InChiKey: FQZKCZBDVYCJMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  54
• 氢给体数：
  0
• 氢受体数：
  6

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  2-氯-6-(三氟甲基)噻唑并[4,5-b]吡啶 、 6-氯-2,3,4,9-四氢-1H-吡啶并[3,4-b]吲哚 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 以39%的产率得到6-chloro-2-[6-(trifluoromethyl)[1,3]thiazolo[4,5-b]pyridin-2-yl]-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole
  参考文献：
  名称：

  Tryptoline-based benzothiazoles re-sensitize MRSA to β-lactam antibiotics

  摘要：

  Resistance-modifying agents (RMAs) offer a promising solution to combat bacterial antibiotic resistance. Here we report the discovery and structure-activity relationships of a new class of RMAs with a novel tryptoline-based benzothiazole scaffold. Our most potent compound in this series (4ad) re-sensitizes multiple MRSA strains to cephalosporins at low concentrations (2 mu g/mL) and has low mammalian cytotoxicity with a half growth inhibitory concentration (GI(50)) > 100 mu g/mL in human cervical carcinoma (HeLa) cells. In addition, the same core scaffold with different substitutions also gives good antibacterial activity against MRSA.

  DOI：

  10.1016/j.bmc.2019.115095

文献信息

• PTERIDINES AND THEIR USE AS AGROCHEMICALS
  申请人：Brewster William K.

  公开号：US20110054173A1

  公开（公告）日：2011-03-03

  The present disclosure relates to 1- or 2-(4-(aryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and 1- or 2-(4-(heteroaryloxy)-phenyl)ethylamino-, oxy- or sulfanyl)pteridines and their use as agrochemicals and animal health products.

  本公开涉及1-或2-(4-(芳氧基)苯基)乙基氨基、氧基或硫基)喹啉和1-或2-(4-(杂芳氧基)苯基)乙基氨基、氧基或硫基)喹啉及其作为农药和动物健康产品的用途。
• Preparation and Use of Biphenyl-4-Yl-Carbonylamino Acid Derivatives for the Treatment of Obesity
  申请人：Smith Roger

  公开号：US20070265298A1

  公开（公告）日：2007-11-15

  This invention relates to certain biphenyl-4-yl carbonylamino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

  本发明涉及某些双苯基-4-基氨基酸羰基化合物、组合物以及用于治疗或预防肥胖症及相关疾病的方法。
• PREPARATION AND USE OF BIPHENYL-4-YL-CARBONYLAMINO ACID DERIVATIVES FOR THE TREATMENT OF OBESITY
  申请人：Smith Roger

  公开号：US20110118302A1

  公开（公告）日：2011-05-19

  This invention relates to certain biphenyl-4-yl carbonylamino acid compounds, compositions, and methods for treating or preventing obesity and related diseases.

  本发明涉及某些联苯-4-基甲酰胺酸化合物、组合物和治疗或预防肥胖及相关疾病的方法。
• Bicyclic heterocyclic compound
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US10793582B2

  公开（公告）日：2020-10-06

  Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.

  本发明提供了一种对 KAT-II 具有卓越抑制作用的新型化合物、其生产方法、其用途以及含有上述化合物的药物组合物等。 一种由式（I）代表的化合物或其药理学上可接受的盐。 其中各符号如说明书中所定义。
• NOVEL BICYCLIC HETEROCYCLIC COMPOUND
  申请人：MITSUBISHI TANABE PHARMA CORPORATION

  公开号：US20190233438A1

  公开（公告）日：2019-08-01

  Provided are a novel compound having a superior inhibitory action on KAT-II, a production method thereof, use thereof, and a pharmaceutical composition containing the aforementioned compound and the like. A compound represented by the formula (I) or a pharmacologically acceptable salt thereof. wherein each symbol is as defined in the DESCRIPTION.